Radium-223 dichloride

BNF:
not listed
Status:
Red
Decision Date:
October 2016
 

Comments

RED1,2,3: NICE TA 412 for treating hormone-relapsed prostate cancer with bone metastases. (Decision date - October 2016). This guidance replaces NICE TA376

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app